Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best biotech penny stocks to buy in 2026. On March 27, Autolus Therapeutics reported Q4 and full-year 2025 financial results, highlighting the commercial scale-up of its CAR T-cell therapy, AUCATZYL. The company achieved net product revenue of $74.3 million for 2025, with $23.3 million generated in Q4. Following its US approval, the therapy launched in the UK in January 2026 under routine commissioning.

Autolus remains optimistic about its commercial trajectory, projecting 2026 revenues between $120 million and $135 million while expecting a shift to positive gross margins during the year. The company is aggressively expanding the clinical utility of its lead candidate, obecabtagene autoleucel (obe-cel), beyond adult B-ALL.

Jirsak / shutterstock.com

Autolus Therapeutics plc (NASDAQ:AUTL) is also pioneering the use of CAR T-cells in autoimmune diseases; the LUMINA trial is currently enrolling patients with severe lupus nephritis, and the BOBCAT trial is exploring its application in progressive multiple sclerosis, with initial data expected by the end of 2026. For long-term growth and margin improvement, the company has initiated a manufacturing life cycle plan focused on automation and a next-gen platform designed to reduce production costs and increase capacity.

Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally.

While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.